The role of endotoxin in septic shock

被引:32
作者
Kellum, John A. [1 ,2 ]
Ronco, Claudio [3 ,4 ]
机构
[1] Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, 600 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA
[2] Spectral Med Inc, Toronto, ON, Canada
[3] St Bortolo Hosp, IRRIV Fdn, Int Renal Res Inst Vicenza, Dept Nephrol Dialysis & Transplantat,aULSS8 Berica, Via Rodolfi 37, I-36100 Vicenza, Italy
[4] Univ Padua, Dept Med DIMED, Via Giustiniani 2, I-35128 Padua, Italy
关键词
Sepsis; Phenotypes; Septic shock; Endotoxin; Endotoxic septic shock; POLYMYXIN-B HEMOPERFUSION; GRAM-NEGATIVE SEPSIS; GENOME-WIDE; MORTALITY; THERAPY; PERITONITIS; ANTIBODIES;
D O I
10.1186/s13054-023-04690-5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Septic shock can be caused by a variety of mechanisms including direct effects of bacterial toxins such as endotoxin. Annually, approximately 5-7 million patients worldwide develop sepsis with very high endotoxin activity in the blood and more than half die. The term endotoxic septic shock has been used for these patients but it is important to emphasize that endotoxin may be a factor in all forms of septic shock including non-bacterial etiologies like COVID-19 since translocation of bacterial products is a common feature of septic shock. A pattern of organ failure including hepatic dysfunction, acute kidney injury and various forms of endothelial dysfunction ranging from disseminated intravascular coagulation to thrombotic microangiopathy characterize endotoxic septic shock. However, while characteristic, the clinical phenotype is not unique to patients with high endotoxin, and the diagnosis relies on the measurement of endotoxin activity in addition to clinical assessment. Therapies for endotoxic septic shock are limited with immune modulating therapies under investigation and extracorporeal blood purification still controversial in many parts of the world.
引用
收藏
页数:7
相关论文
共 50 条
[31]   Does Continuous Renal Replacement Therapy with oXiris in Septic Shock Have Any Positive Impact? Single-Centre Experience with oXiris Therapy in Septic Shock Patients [J].
Mielnicki, Wojciech ;
Dyla, Agnieszka ;
Zajac, Marta ;
Rokicka-Demitraszek, Natalia ;
Smereka, Jacek .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (24)
[32]   The ability of endotoxin adsorption during a longer duration of direct hemoperfusion with a polymyxin B-immobilized fiber column in patients with septic shock [J].
Shimizu, Tomoharu ;
Obata, Toru ;
Sonoda, Hiromichi ;
Akabori, Hiroya ;
Tabata, Takahisa ;
Eguchi, Yutaka ;
Endo, Yoshihiro ;
Tani, Tohru .
TRANSFUSION AND APHERESIS SCIENCE, 2013, 49 (03) :499-503
[33]   Septic circulatory shock and septic cardiomyopathy [J].
Werdan, K. ;
Hettwer, S. ;
Bubel, S. ;
Oelke, A. ;
Hoke, R. S. ;
Wimmer, R. ;
Ebelt, H. ;
Mueller-Werdan, U. .
INTERNIST, 2009, 50 (07) :799-+
[34]   Endotoxin hemoadsorption in refractory septic shock with multiorgan dysfunction and extreme endotoxin activity [J].
Ruiz-Rodriguez, Juan Carlos ;
Chiscano-Camon, Luis ;
Bajana, Ivan ;
Ruiz-Sanmartin, Adolf ;
Bastidas, Juliana ;
Maldonado, Carolina ;
Nicolas-Morales, Pablo ;
Cantenys-Molina, Sergi ;
Gonzalez, Juan Jose ;
Larrosa, Nieves ;
Ferrer, Ricard .
CRITICAL CARE, 2025, 29 (01)
[35]   Endotoxin Elimination in Patients with Septic Shock: An Observation Study [J].
Adamik, Barbara ;
Zielinski, Stanislaw ;
Smiechowicz, Jakub ;
Kuebler, Andrzej .
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2015, 63 (06) :475-483
[36]   An update on membranes and cartridges for extracorporeal blood purification in sepsis and septic shock [J].
Honore, Patrick M. ;
De Bels, David ;
Spapen, Herbert D. .
CURRENT OPINION IN CRITICAL CARE, 2018, 24 (06) :463-468
[37]   Endotoxin removal devices for the treatment of sepsis and septic shock [J].
Davies, B. ;
Cohen, J. .
LANCET INFECTIOUS DISEASES, 2011, 11 (01) :65-71
[38]   Effects of polymyxin B hemoperfusion on hemodynamics and prognosis in septic shock patients [J].
Lee, Chen-Tse ;
Tu, Yu-Kang ;
Yeh, Yi-Chun ;
Chang, Tzu ;
Shih, Po-Yuan ;
Chao, Anne ;
Huang, Hsing-Hao ;
Cheng, Ya-Jung ;
Yeh, Yu-Chang .
JOURNAL OF CRITICAL CARE, 2018, 43 :202-206
[39]   Use of extracorporeal endotoxin elimination therapy for septic shock [J].
BA Adamik ;
JS Smiechowicz ;
SZ Zielinski ;
AK Kübler .
Critical Care, 17 (Suppl 2)
[40]   Tumor necrosis factor, interleukin-6, endotoxin and procalcitonin in septic shock in patients with hematological malignancy [J].
Galstyan, GM ;
Berkovsky, AL ;
Zueva, VA ;
Karyakin, AV ;
Levina, AA ;
Sergeeva, EV ;
Speranskaya, LL ;
Gorodetsky, VM .
TERAPEVTICHESKII ARKHIV, 2002, 74 (07) :56-61